InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.004 -0.001 (-11.11%)+
Announcement
Release
30 Apr 2026 8:57AM
Price at Release
$0.005
Full Release
download
Summary
Percheron Therapeutics Limited, a biotechnology company focused on novel therapies for oncology and rare diseases, has reported significant activities in its quarterly report ending 31 March 2026. The company successfully raised $2.2 million to fund its lead program HMBD-002, which is advancing to a phase II clinical trial. The drug has shown promising safety and tolerability in phase I trials and has been featured in international conferences. The company's financials indicate a cash balance of $3.10 million, with a net cash outflow of $1.36 million for the quarter. With funds raised and strategic manufacturing partnerships in place, Percheron is well-positioned for future clinical developments.
Key Points
  • Percheron Therapeutics Limited raised $2.2 million through a non-renounceable entitlement offer.
  • The company's lead program, HMBD-002, is progressing towards a phase II clinical trial.
  • HMBD-002 has been presented at international scientific conferences including AACR and ASCO.
  • Percheron's licensor, Hummingbird Bioscience, is manufacturing a new batch of HMBD-002 drug substance.
  • The company had a net cash outflow of $1.36 million for the quarter ending 31 March 2026.
  • Percheron closed the quarter with $3.10 million in cash, prior to the capital raised in April 2026.
  • The financial report indicates 2.3 quarters of funding available based on cash flow.
  • Percheron's financial activities report is consistent with ASX Listing Rule requirements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.